Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
Myasthenia Gravis (MG) has had significant advances, however critical gaps persist in optimizing care. Challenges include variability in diagnostic accuracy, particularly in seronegative cases, and a limited adoption of newer, more sensitive testing modalities. Additionally, the evolving treatment landscape—with emerging therapies such as complement inhibitors and FcRn antagonists—highlights the need for clinicians to stay informed about the latest evidence and integrate these options into personalized care strategies. Addressing these gaps is crucial to improving patient care, enhancing quality of life, and reducing the burden of long-term side effects associated with traditional treatments.

This special edition podcast series with Dr. Nicholas Silvestri enables healthcare providers to engage with evidence-based insights and practical guidance on MG management at their convenience. The podcast format is ideal for professionals to access while commuting, during breaks, or between patient appointments, providing targeted learning without disrupting their workflow.

Activity Summary:
In this Clinical Clip, Dr. Nicholas Silvestri provides a concise and clinically relevant summary of the most important emerging data presented at AAN 2025 that impact the management of generalized Myasthenia Gravis (gMG).

Topics covered include pivotal updates from recent clinical trials—such as MINT (inebilizumab), ADAPT NXT (efgartigimod), and MycarinG (rozanolixizumab)—highlighting the safety, efficacy, and practical implications of emerging therapies across diverse MG subtypes. The activity also explores trends in real-world treatment patterns, therapeutic inertia among neurologists, and new diagnostic approaches including advanced serologic testing and AI-supported electrophysiologic tools. With a focus on individualized care, this activity equips healthcare professionals with key insights to help integrate new therapies and diagnostic innovations into practice, ultimately supporting timely, targeted, and patient-centered management of MG.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.

Activity Summary:
Vitiligo is a relatively common acquired pigmentation disorder. The therapeutic effect of all the treatment modalities varies considerably from individual to individual. As such, treatment must be individualized. Moreover, vitiligo can carry significant psychosocial impact. Healthcare providers play a crucial role in shaping patients' understanding of their condition, approach to treatment, and coping mechanisms. In this podcast series, Dr. Raj Chovatiya, along with his patient, will discuss ways to individualized treatment strategies and improve holistic care of patients with vitiligo.

Activity Summary:
This podcast series features engaging discussions between leading experts and their patients with primary biliary cholangitis (PBC). The patients share their insights and experiences with PBC, its treatment, and key learning experiences in their journeys with PBC. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at AASLD 2024. In these video Clips, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. 

In this video presentation, Dr Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Activity Summary:
Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In this podcast series, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.

Activity Summary:
Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In these mini modules, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.

Activity Summary:
Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is associated with frequent bruising and bleeding. Current evidence suggests that low platelet counts in ITP are the result of multiple factors. Heterogeneity in patient population and characteristics make it challenging for the clinicians to choose appropriate therapeutic regimen. Clinicians must make decisions on the basis of the clinical presentation of each individual patient, ideally through a shared decision-making process that considers the patient’s values and preferences with respect to the anticipated outcomes of the chosen option.

In this webcast archive, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes.

Activity Summary:
During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.

Activity Summary:
During this webcast archive, Dr. Angela Weyand and Dr. Guy Young will discuss the latest practice-changing updates and breakthroughs in hemophilia A treatment paradigms, to ultimately improve outcomes among patients.

Please see the downloadable slides as a resource for key discussion and teaching points.

Activity Summary:
During this accredited continuing education series of two (2) podcasts as downloadable audio files, Dr. Raj Chovatiya and Dr. David Rosmarin will provide expert interpretation of new data for current and emerging treatment options of vitiligo. Additionally, practical considerations for how new agents can impact patient outcomes will be discussed. Case presentations will be reviewed to help clinicians select the most appropriate treatment as well as address the significant health burdens and complications experienced by many patients during treatment.

Activity Summary:
During this webcast archive, Dr. Raj Chovatiya and Dr. David Rosmarin provide expert interpretation of new data for current and emerging treatment options of vitiligo, along with practical considerations for how new agents can impact patient outcomes. Case presentations will be discussed to help clinicians select the most appropriate treatment as well as address the significant health burdens and complications experienced by many patients during treatment.

Please click the ‘Download Slides’ or ‘View Slides' button for access to the supplemental slides as your educational resource.

Activity Summary:
Clinical Viewpoints HLH/MAS includes a curriculum that highlights the very latest clinical data in hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Slides are developed and updated throughout the year by leading HLH/MAS expert physicians. All content is reviewed and approved by the Clinical Viewpoints HLH/MAS Planning Committee.

The current initial treatment for hemophagocytic lymphohistiocytosis (HLH) and/or macrophage activation syndrome (MAS) aims to suppress the excessive activation of the immune system and treat the cytokine storm. However, contemporary HLH and MAS management is an evolving science that builds off each advance in basic/clinical research and clinical experience. This case-based slide kit discusses current controversies in the management of secondary HLH, including MAS.

Activity Summary:
Talking Hemophilia A is a roundtable discussion continuing education activity designed to inform and guide on integrating novel therapies into hemophilia A treatment paradigms.

The expert faculty presenters will provide an overview of existing approaches and their limitations and how new and emerging therapies can be used to address unmet needs. The activity will be supported by downloadable, supplemental slides that have the key discussion and teaching points.

Activity Summary:
Lightning Reports are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. These activities are designed to keep healthcare professionals on top of the most recent clinical findings.

This series of accredited continuing education enduring videos will provide brief commentary spotlighting hot topics in myelodysplastic syndromes (MDS) presented at the 2022 American Society for Hematology (ASH) Annual Meeting from New Orleans, Louisiana.

Activity Summary:
The Talking Post-Transplant Acute Myeloid Leukemia (AML) webcast series will provide recent updates to improve outcomes in post-transplantation relapse in AML.

This webcast series, led by expert faculty, will provide guidance and practical strategies to safely implement recent progress in addressing post-transplantation relapse in AML. Through patient cases and scenarios, faculty presenters will guide the integration of new evidence into clinical treatment paradigms of AML in the post-transplantation setting. The activity will be supported by downloadable slides that have the key discussion/teaching points.

*Healthcare providers may only claim for the participation of one (1) enduring archive activity.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

Patients with PH-ILD face a dismal prognosis and are associated with reduced exercise capacity, greater need for supplemental oxygen, and a decreased quality of life. In recent years, there have been several advances in the treatment and management of PH-ILD. This slide kit will use three case scenarios to illustrate best-practice approaches to accurately diagnose PH-ILD and differentiate it from group 1 pulmonary arterial hypertension (PAH). It will also provide guidance on integrating recent progress in the treatment of PH-ILD and on the safe and effective use of approved and emerging therapy.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to bruising and bleeding. For many years, immune-modulating therapies, such as corticosteroids, immunoglobulins (IVIG and anti-RhD), and rituximab, were the mainstays of treatment in ITP. Since 2008, the approval of thrombopoietin-receptor agonists (TPO-RAs) including a second-generation oral TPO-RA and a spleen tyrosine kinase (Syk) inhibitor, revolutionized the treatment landscape of ITP by opening new and highly effective avenues of treatment. This landscape will be further transformed with a sizable clinical pipeline including inhibitors of CD20, CD40, neonatal Fc receptor (FcRn), bruton’s tyrosine kinase (BTK), and Syk signaling.

This slide kit is designed to keep busy clinicians abreast of the emerging evidence for available treatments and the novel therapy pipeline, to optimize the treatment and care for patients with ITP.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.